Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of “Moderate Buy” from Analysts

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has been given a consensus recommendation of “Moderate Buy” by the eighteen analysts that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation and sixteen have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $215.20.

Several brokerages have weighed in on AXSM. TD Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research report on Thursday, January 29th. Needham & Company LLC reissued a “buy” rating and set a $225.00 price target on shares of Axsome Therapeutics in a research note on Monday, January 5th. Leerink Partners upped their price target on Axsome Therapeutics from $150.00 to $205.00 and gave the stock an “outperform” rating in a report on Wednesday, January 28th. Royal Bank Of Canada raised their price objective on Axsome Therapeutics from $212.00 to $219.00 and gave the company an “outperform” rating in a research note on Wednesday, January 21st. Finally, Piper Sandler boosted their target price on Axsome Therapeutics from $148.00 to $223.00 and gave the stock an “overweight” rating in a research report on Friday, January 16th.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $184.74 on Thursday. The firm’s fifty day simple moving average is $172.42 and its 200-day simple moving average is $143.04. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. The stock has a market cap of $9.31 billion, a PE ratio of -39.56, a price-to-earnings-growth ratio of 11.83 and a beta of 0.40. Axsome Therapeutics has a fifty-two week low of $86.99 and a fifty-two week high of $191.50.

Insider Transactions at Axsome Therapeutics

In related news, Director Mark E. Saad sold 37,577 shares of the business’s stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total value of $6,206,968.86. Following the sale, the director directly owned 10,002 shares in the company, valued at $1,652,130.36. The trade was a 78.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ari Maizel sold 7,500 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total transaction of $1,383,300.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 308,874 shares of company stock worth $51,390,805. Corporate insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Versant Capital Management Inc lifted its stake in Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock valued at $25,000 after buying an additional 203 shares in the last quarter. Kemnay Advisory Services Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter worth $31,000. First Horizon Corp purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at $34,000. Optiver Holding B.V. boosted its stake in shares of Axsome Therapeutics by 82.3% during the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the last quarter. Finally, Ameriflex Group Inc. acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $37,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.